Get the Stockscreener App
18.45
0.78%
-0.145
After Hours:
18.89
0.44
+2.38%
Capricor Therapeutics Inc stock is traded at $18.45, with a volume of 651.39K.
It is down -0.78% in the last 24 hours and down -14.78% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$18.59
Open:
$18.65
24h Volume:
651.39K
Relative Volume:
0.22
Market Cap:
$839.56M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-15.77
EPS:
-1.17
Net Cash Flow:
$-33.33M
1W Performance:
-16.10%
1M Performance:
-14.78%
6M Performance:
+237.29%
1Y Performance:
+542.86%
1-Day Range:
$18.01
$19.30
1-Week Range:
$18.01
$22.90
52-Week Range:
$2.68
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 - The Manila Times
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3%Time to Sell? - MarketBeat
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength - Yahoo Finance
Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Piper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight Recommendation - MSN
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Capricor Therapeutics initiated at Overweight by Piper Sandler - MSN
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3%Here's Why - MarketBeat
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics stock outlook driven by DMD drug potential, says Piper Sandler - Investing.com Canada
Cash raises for Inventiva, Akeso, Capricor - BioCentury
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Capricor Therapeutics Announces Closing of Underwritten - GlobeNewswire
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - StockTitan
Form 424B5 CAPRICOR THERAPEUTICS, - StreetInsider.com
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownHere's What Happened - MarketBeat
Why Capricor Therapeutics (CAPR) Shares Are Trading Lower - Benzinga
Capricor Therapeutics Stock Slides After Pricing Secondary Offering, Catches Retail’s Eye - Barchart
Capricor sets public offering at $17 per share - Investing.com
Capricor Therapeutics Shares Slip Premarket on Stock Offering - MarketWatch
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock - The Manila Times
Capricor sets public offering at $17 per share By Investing.com - Investing.com UK
Capricor Therapeutics to file BLA for DMD treatment By Investing.com - Investing.com South Africa
Capricor Therapeutics to file BLA for DMD treatment - Investing.com India
Capricor Therap stock soars to 52-week high of $22.05 By Investing.com - Investing.com Australia
Capricor Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 2.5%What's Next? - MarketBeat
Nothing is Better Than Capricor Therapeutics Inc (CAPR) stock at the moment - SETE News
Capricor Therap stock soars to 52-week high of $22.05 - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 0.8%Time to Buy? - MarketBeat
Investing in Capricor Therapeutics Inc (CAPR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
CAPR’s Market Whiplash: 300.41% YTD Rise, 326.58% Rise in 30 Days - The InvestChronicle
Investing in Capricor Therapeutics Inc (CAPR): What You Must Know - Knox Daily
Capricor Therapeutics (NASDAQ:CAPR) Trading 5.2% HigherHere's What Happened - MarketBeat
Cardiac Data Strengthens Capricor’s Duchenne Candidate As FDA Filing Gets Underway - Scrip
Metric Deep Dive: Understanding Capricor Therapeutics Inc (CAPR) Through its Ratios - The Dwinnex
Capricor touts long-term efficacy of DMD therapy ahead of FDA application - Yahoo! Voices
Oppenheimer reiterates Capricor at Outperform on Deramiocel optimism By Investing.com - Investing.com Canada
Capricor reports positive long-term data for DMD drug deramiocel - MSN
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Decline in Short Interest - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Capricor reports positive 3-year DMD treatment results By Investing.com - Investing.com Canada
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years - AOL
What is going on with Capricor Therapeutics Inc? Sentiment Analysis - US Post News
Capricor reports positive long-term data for DMD drug deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpShould You Buy? - MarketBeat
Capricor Therapeutics Stock Jumps As HC Wainwright Boosts Price Target On DMD Drug Potential: Retail Buzz Grows - Barchart
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):